Area of research
Oncology · Cancer Research
Research interest
Research interests include Cancer Diagnosis and Treatment, Cancer Genomics and Diagnostics, Acute Myeloid Leukemia Research, and Cancer-related Molecular Pathways.
Corrigendum to “Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group”
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study
Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
1804P Baseline mutational profiles of patients (pts) with carcinoma-of-unknown-primary-origin (CUP) enrolled onto CUPISCO
Diagnostik und Therapie von Krebserkrankungen mit unbekanntem Primärtumor (CUP-Syndrom)
519P Patterns of care and outcomes in carcinoma of unknown primary: A SEER-Medicare study
A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
Comprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO: A phase II, randomised, multicentre study comparing targeted therapy or immunotherapy with standard platinum-based chemotherapy
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide
Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
Strategies for improving the solubility and metabolic stability of griseofulvin analogues
Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia
DNA damage-induced centrosome amplification occurs via excessive formation of centriolar satellites
Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost‐effective and safer treatment of advanced follicular lymphoma